Cagrisema Novo Nordisk

Novo Nordisk shares drop

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Investopedia on MSN · 3d

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

Seeking Alpha · 3d

Novo Nordisk: CagriSema Disappoints Again

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.

PharmiWeb3d

Novo Nordisk A/S: CagriSema demonstrates superior…

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...

20h

Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

22hon MSN

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

23h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results